Utility of amniotic fluid chitotriosidase in the prenatal diagnosis of lysosomal storage disorders.
Clin Biochem 2018;
61:40-44. [PMID:
30205089 DOI:
10.1016/j.clinbiochem.2018.09.004]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Revised: 09/06/2018] [Accepted: 09/07/2018] [Indexed: 11/18/2022]
Abstract
OBJECTIVE
Plasma chitotriosidase is a documented biomarker for certain lysosomal storage disorders. However, its clinical utility for prenatal samples is not elucidated yet.
METHODS
We have established Reference intervals for amniotic fluid chitotriosidase using control amniotic fluids (n = 47) and compared the activity with amniotic fluids affected by lysosomal storage disorders (n = 25).
RESULTS
The reference interval established was 0-6.76 nmol/h/ml. The amniotic fluids affected with LSDs exhibited elevation of chitotriosidase. The area under the curve (AUC) of receiver operating characteristic curve for affected vs. healthy was 0.987 indicating 98.6% accuracy of chitotriosidase in identifying pregnancies affected with LSDs. Among the different LSDs, Gaucher (202.00 ± 35.27 nmol/h/ml) and Niemann-pick A/B (60.33 ± 21.59 nmol/h/ml) showed very high levels of chitotriosidase.
CONCLUSION
Amniotic fluid chitotriosidase has the potential to serve as a diagnostic marker for lysosomal storage disorders, more specifically for Gaucher and Niemann-Pick A/B.
Collapse